Cyfuse Biomedical K.K. (TYO:4892)

Cyfuse Biomedical K.K. Income Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	54	61	374	708	137
Revenue Growth (YoY)	-11.47%	-83.69%	-47.17%	416.79%	12.47%
Cost of Revenue	38	23	133	137	70
Gross Profit	16	38	241	571	67
Selling, General & Admin	428	351	346	500	439
Research & Development	469	375	303	-	-
Operating Expenses	912	735	666	500	439
Operating Income	-896	-697	-425	71	-372
Interest Expense	-10	-10	-7	-5	-5
Currency Exchange Gain (Loss)	-	-	-1	-	-
Other Non Operating Income (Expenses)	36	121	-	78	50
EBT Excluding Unusual Items	-870	-586	-433	144	-327
Other Unusual Items	-	-	-38	-	-
Pretax Income	-870	-586	-471	144	-327
Income Tax Expense	2	3	2	2	2
Net Income to Company	-872	-589	-473	142	-329
Net Income	-872	-589	-473	142	-329
Net Income to Common	-872	-589	-473	142	-329
Shares Outstanding (Basic)	8	8	3	1	1
Shares Outstanding (Diluted)	8	8	3	1	1
Shares Change (YoY)	3.05%	192.85%	432.99%	-	-
EPS (Basic)	-108.31	-75.39	-177.31	283.72	-657.34
EPS (Diluted)	-108.31	-75.39	-177.31	283.72	-657.34
Free Cash Flow	-768	-581	-631	-	-
Free Cash Flow Per Share	-95.40	-74.37	-236.54	-	-
Gross Margin	29.63%	62.30%	64.44%	80.65%	48.91%
Operating Margin	-1659.26%	-1142.62%	-113.64%	10.03%	-271.53%
Profit Margin	-1614.82%	-965.57%	-126.47%	20.06%	-240.15%
Free Cash Flow Margin	-1422.22%	-952.46%	-168.72%	-	-
EBITDA	-858	-657	-362	-	-
EBITDA Margin	-	-	-96.79%	-	-
D&A For EBITDA	38	40	63	-	-
EBIT	-896	-697	-425	71	-372
EBIT Margin	-	-	-113.64%	10.03%	-271.53%
Effective Tax Rate	-	-	-	1.39%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.